Please try another search
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Name | Age | Since | Title |
---|---|---|---|
Zami Aberman | 68 | 2005 | Chairman |
Yaacov Yanay | 51 | 2013 | President, CEO & Director |
Doron Birger | 71 | 2021 | Independent Director |
Maital Shemesh-Rasmussen | 52 | 2021 | Independent Director |
Rami Avraham Levi | 60 | 2021 | Independent Director |
Yoram Palti | 85 | 2022 | Member of Strategic Advisory Board |
Eilon Tirosh | - | 2022 | Member of Strategic Advisory Board |
Prasad S. Adusumilli | - | 2024 | Member of Scientific Advisory Board |
James Roosevelt | 78 | 2024 | Member of Advisory Board |
Richard L. Kendall | 70 | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review